Inclusion Criteria:

          1. For Dose Escalation:

               1. Have a histologically confirmed diagnosis of advanced metastatic or progressive
                  solid tumor excluding tumor types with rapid cell turnover, ie, small cell cancer
                  (lung and extra pulmonary), inflammatory breast cancer (IBC), medulloblastoma,
                  neuroblastoma and melanoma with extensive liver metastasis (greater than or equal
                  to 50% of the liver involved; patients with melanoma and metastasis to less than
                  50% of the liver are eligible)

               2. Be refractory to, or intolerant of, established therapy known to provide clinical
                  benefit for their condition.

          2. For Dose Expansion:

               1. Patients who have a histologically confirmed locally advanced or metastatic
                  unresectable sarcoma

               2. Have received at least one prior line of treatment (but no more than 3 prior
                  lines) including an anthracycline.

          3. Have one or more measurable tumors measurable or evaluable as outlined by modified
             Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

          4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or
             equal to 1

          5. Have a life expectancy greater than or equal to 3 months at the time of informed
             consent/assent.

          6. Be greater than or equal to 18 years of age for dose escalation and expansion;
             Patients aged 16 and 17 may also participate in dose expansion if they weigh ≥40 kg

          7. Have a negative pregnancy test (if female of childbearing potential)

          8. Have acceptable liver function:

               1. Bilirubin less than or equal to 1.5x upper limit of normal (ULN) (unless
                  attributed to Gilbert's syndrome)

               2. Aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT) and
                  alkaline phosphatase less than or equal to 2.5x upper limit of normal (ULN) *If
                  liver metastases are present, then less than or equal to 5x ULN is allowed.

                    -  If bone metastases are present, but bilirubin, AST, ALT are ≤2.5x ULN, then
                       there is no upper limit for alkaline phosphatase level. Radiographic proof
                       of bone involvement is required, and alkaline phosphatase fractionation is
                       strongly recommended to confirm the elevation is due to bony metastases.

          9. Have acceptable renal function:

             a. Calculated creatinine clearance greater than or equal to 30 mL/min

         10. Have acceptable hematologic status:

               1. Granulocyte greater than or equal to 1500 cells/mm3

               2. Platelet count greater than or equal to 100,000 (plt/mm3)

               3. Hemoglobin greater than or equal to 8 g/dl

         11. Have acceptable coagulation status:

               1. Prothrombin time (PT) within 1.5x normal limits

               2. Activated partial thromboplastin time (aPTT) within 1.5x normal limits

         12. Be nonfertile or agree to use an adequate method of contraception. Sexually active
             patients and their partners must use an effective method of contraception (hormonal or
             barrier method of birth control; or abstinence) prior to study entry and for the
             duration of study participation including for at least 3 months (males) and 6 months
             (females) after the last dose of study drug. Should a woman become pregnant or suspect
             she is pregnant while participating in this study, she should inform her treating
             physician immediately.

         13. Have read and signed the Institutional Review Board (IRB)-approved informed consent
             form (ICF) prior to any study related procedure. (In the event that the patient is
             re-screened for study participation or a protocol amendment alters the care of an
             ongoing patient, a new ICF must be signed.) Assent is also required for patients who
             have not attained the legal age of consent for treatments or procedures involved in
             research.

        Exclusion Criteria:

          1. History of congestive heart failure (CHF), greater than New York Heart Association
             (NYHA) Class III, myocardial infarction within the past 6 months prior to Cycle 1 Day
             1, left ventricular ejection fraction (LVEF) less than 45% by echocardiogram (ECHO) or
             multigated acquisition scan (MUGA), uncontrolled unstable arrhythmia, or evidence of
             ischemia on electrocardiogram (ECG) within 14 days prior to Cycle 1 Day 1

          2. Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of >450
             msec in men and >470 msec in women

          3. Have a seizure disorder requiring anticonvulsant therapy

          4. Presence of symptomatic central nervous system metastatic disease or disease that
             requires local therapy such as radiotherapy, surgery, or increasing dose of steroids
             within the prior 2 weeks. Patients with previously treated and/or controlled
             metastasis are eligible.

          5. Have severe chronic obstructive pulmonary disease with hypoxemia (defined as resting
             02 saturation of less than or equal to 90% breathing room air)

          6. Have undergone major surgery within 2 weeks prior to Cycle 1 Day 1

          7. Have active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy, including known, active COVID-19

          8. Are pregnant or nursing

          9. Received treatment with surgery, chemotherapy, or investigational therapy within 28
             days or 5 half-lives, whichever occurs first, prior to study entry (6 weeks for
             nitrosoureas or Mitomycin C) and 2 weeks for radiation therapy.

         10. Are unwilling or unable to comply with procedures required in this protocol

         11. Have known infection with human immunodeficiency virus (HIV), hepatitis B, or
             hepatitis C. Patients with history of chronic hepatitis that is currently not active
             are eligible.

         12. Have a serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other
             conditions) that could compromise protocol objectives in the opinion of the
             investigator and/or the sponsor

         13. Are currently receiving any other investigational agent

         14. Have exhibited allergic reactions to a similar structural compound, biological agent,
             or formulation

         15. Have symptomatic malabsorption conditions (eg, Crohn's disease, etc) or Have undergone
             significant surgery to the gastrointestinal tract that could impair absorption or that
             could result in short bowel syndrome with diarrhea due to malabsorption